Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals was a biotechnology company developing nitroxyl-based therapies for cardiovascular disease. Its lead investigational candidate, CXL-1427, targeted acute decompensated heart failure. Bristol-Myers Squibb acquired the company in December 2015.